“With the surge of states requiring physicians to notify patients that they have dense breast tissue, a solution must evolve to address this at-risk patient population,” said Royea. “This condition is more difficult to interpret with standard imaging alternatives and is associated with higher risk for breast cancer. FWS has now completed five years of research and development to ensure accurate, reproducible outcomes for breast cancer screening, focusing on mitotic cellular activity and proteomics. As this solution can work on any age and any tissue type, the FWS solution can create significant health management value for women worldwide while providing a protocol for clinicians to manage early onset situations.”
According to Royea, analysts indicate the worldwide value in the marketplace exceeds $3 billion. Holmes, who has been acting as CEO, will return to his CFO position and remain chairman of the board.
About First Warning Systems
First Warning Systems (FWS), founded in 2008, is based in Reno, Nevada. FWS’s principal shareholder is Lifeline Biotechnologies, Inc. (OTC Market: LLBO). FWS holds the exclusive development, manufacturing and marketing worldwide license from Lifeline to commercialize its intellectual property. The FWS product line is a device and process that detects breast tissue abnormalities leading to health risk assessment and management and, potentially, breast cancer. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a European CE Mark to mar
Copyright©2012 Vocus, Inc.
All rights reserved